BACKGROUND: The genes RAS and BRAF have been shown to be frequently mutated in human thyroid carcinomas. The aim of this study was to genotype a cohort of 55 sporadic papillary thyroid carcinomas (PTC) and 44 sporadic medullary thyroid carcinomas (MTC) for the K-RAS codon 12 and BRAF codon 600 mutations. MATERIALS AND METHODS: K-RAS and BRAF mutations were characterized by an enhanced polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR-RFLP). RESULTS: The K-RAS codon 12 mutation was found in 54.5% of the PTC and 40.9% of the MTC cases tested. The BRAF V600E mutation was detected in 27.3% of the PTC and 68.2% of the MTC samples. No significant association between K-RAS and BRAF mutations and clinicopathological parameters was found. CONCLUSION: These data indicate that K-RAS and BRAF mutations were a frequent genetic event in our samples of sporadic PTC and MTC.
BACKGROUND: The genes RAS and BRAF have been shown to be frequently mutated in humanthyroid carcinomas. The aim of this study was to genotype a cohort of 55 sporadic papillary thyroid carcinomas (PTC) and 44 sporadic medullary thyroid carcinomas (MTC) for the K-RAS codon 12 and BRAF codon 600 mutations. MATERIALS AND METHODS:K-RAS and BRAF mutations were characterized by an enhanced polymerase chain reaction followed by restriction fragment length polymorphism analysis (PCR-RFLP). RESULTS: The K-RAS codon 12 mutation was found in 54.5% of the PTC and 40.9% of the MTC cases tested. The BRAFV600E mutation was detected in 27.3% of the PTC and 68.2% of the MTC samples. No significant association between K-RAS and BRAF mutations and clinicopathological parameters was found. CONCLUSION: These data indicate that K-RAS and BRAF mutations were a frequent genetic event in our samples of sporadic PTC and MTC.
Authors: Razelle Kurzrock; Steven I Sherman; Douglas W Ball; Arlene A Forastiere; Roger B Cohen; Ranee Mehra; David G Pfister; Ezra E W Cohen; Linda Janisch; Forlisa Nauling; David S Hong; Chaan S Ng; Lei Ye; Robert F Gagel; John Frye; Thomas Müller; Mark J Ratain; Ravi Salgia Journal: J Clin Oncol Date: 2011-05-23 Impact factor: 44.544
Authors: R Ciampi; C Romei; L Pieruzzi; A Tacito; E Molinaro; L Agate; V Bottici; F Casella; C Ugolini; G Materazzi; F Basolo; R Elisei Journal: J Endocrinol Invest Date: 2016-08-17 Impact factor: 4.256
Authors: V Sykorova; S Dvorakova; A Ryska; J Vcelak; E Vaclavikova; J Laco; D Kodetova; R Kodet; A Cibula; J Duskova; A Hlobilkova; J Astl; D Vesely; J Betka; J Hoch; S Smutny; J Cap; P Vlcek; Z Novak; B Bendlova Journal: J Endocrinol Invest Date: 2009-12-04 Impact factor: 4.256
Authors: Bálint Tobiás; Csaba Halászlaki; Bernadett Balla; János P Kósa; Kristóf Árvai; Péter Horváth; István Takács; Zsolt Nagy; Evelin Horváth; János Horányi; Balázs Járay; Eszter Székely; Tamás Székely; Gabriella Győri; Zsuzsanna Putz; Magdolna Dank; Zsuzsanna Valkusz; Béla Vasas; Béla Iványi; Péter Lakatos Journal: Pathol Oncol Res Date: 2015-08-11 Impact factor: 3.201
Authors: A Boichard; L Croux; A Al Ghuzlan; S Broutin; C Dupuy; S Leboulleux; M Schlumberger; J M Bidart; L Lacroix Journal: J Clin Endocrinol Metab Date: 2012-08-03 Impact factor: 5.958